Aelis Farma Receives a Second Positive Recommendation From the Independent Data Monitoring Committee for Its Phase 2b Study with AEF0217 in People With Down syndrome

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for diseases involving the CB1 receptor, today announces a second positive recommendation from the Independent Data Monitoring Committee (“IDMC”) reviewing the safety data of the ongoing Phase 2b study with AEF0217 in adults and older adolescents (16-17 years of age) with Down syndrome. Following this revie

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.